- $282.83m
- $262.44m
- $29.80m
- 97
- 51
- 29
- 61
Annual income statement for NVE, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 25.4 | 21.4 | 27 | 38.3 | 29.8 |
Cost of Revenue | |||||
Gross Profit | 20.5 | 17.2 | 20.7 | 30.2 | 23 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 9.9 | 8.62 | 10.7 | 12.6 | 11.3 |
Operating Profit | 15.5 | 12.7 | 16.3 | 25.6 | 18.5 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 17.3 | 14.2 | 17.5 | 27.1 | 20.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 14.5 | 11.7 | 14.5 | 22.7 | 17.1 |
Net Income Before Extraordinary Items | |||||
Net Income | 14.5 | 11.7 | 14.5 | 22.7 | 17.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 14.5 | 11.7 | 14.5 | 22.7 | 17.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3 | 2.42 | 3 | 4.7 | 3.54 |
Dividends per Share |